Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Bagcilar Training and Research Hospital

Status: Completed

Conditions: Prostate Cancer Detection

Study type: Observational

Funder types: Other

Identifiers

NCT02013180

Zinc/PSA

Details and patient eligibility

About

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.

In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.

In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Enrollment: 480 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination

Exclusion criteria

usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.

Trial design

480 participants in 2 patient groups

prostate cancer

Description:

prostate adenocarcinoma in pathologic evaluation

control

Description:

benign prostatic diseases in pathologic evaluation